Revvity

We’re not waiting for change, we’re driving it. In this series, we highlight how our people, our customers, and our technologies are transforming healthcare challenges into real-world breakthroughs to improve lives around the globe.

On World Preeclampsia Day, we recognize the power of earlier insight. Research like the ASPRE study is helping shift preeclampsia care toward earlier risk assessment and prevention, enabling clinicians to act sooner. Read our latest Stories from Revvity. #WorldPreeclampsiaDay #ChallengeAccepted #MaternalHealth

To minimize the shock of Type 1 Diabetes diagnosis, clinicians and researchers have been working to identify at risk children before symptoms appear, so that these children can be monitored and supported as early as possible. That’s where the story of screening begins, not just with science, but with finding a way to help minimize the worry, stress, and legitimate concern for the approximately 350,000 families worldwide who are affected with Type 1 Diabetes every year.

The challenge isn't creating more data. It's connecting it. See how Revvity and Lilly are collaborating to helping bridge the gap between isolated data and shared intelligence, bringing AI into everyday drug discovery while keeping data secure. Read the latest Stories from Revvity. #ChallengeAccepted #AI #DrugDiscovery Eli Lilly and Company

We’re not waiting for change we’re driving it. Subscribe to this newsletter series to follow how our people, customers, and technologies turn today’s challenges into tomorrow’s breakthroughs.

Imagine if, just days after birth, doctors knew whether a baby is at risk for a rare but treatable disease, before symptoms appear. It’s the promise of next-generation sequencing (NGS), a powerful technology reshaping how we understand and protect newborn health. Continue reading in our newsletter!